New era: Prophylactic surgery for patients with multiple endocrine neoplasia-2A

ANZ Journal of Surgery

Volumn 76, Issue 7, 2006, Pages 586-590

  Gosnell, Jessica E ^a   Sywak, Mark S ^a   Sidhu, Stan B ^a   Gough, Ian R ^d   Learoyd, Diana L ^b,c   Robinson, Bruce G ^b,c   Delbridge, Leigh W ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Hyperparathyroidism; Medullary thyroid carcinoma; MEN 2A; Total thyroidectomy

Indexed keywords

CALCITONIN;

ADOLESCENT; ADULT; ARTICLE; C CELL HYPERPLASIA; CALCITONIN BLOOD LEVEL; CANCER FAMILY; CANCER RISK; CELL HYPERPLASIA; CLINICAL ARTICLE; CODON; FEMALE; GENE MUTATION; GENE REARRANGEMENT; GENETIC TRANSFECTION; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; LYMPH NODE DISSECTION; MALE; MULTIPLE ENDOCRINE NEOPLASIA; PARATHYROID DISEASE; PHEOCHROMOCYTOMA; PREOPERATIVE EVALUATION; PROPHYLACTIC SURGERY; PROPHYLAXIS; PROTO ONCOGENE; SCHOOL CHILD; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

ADOLESCENT; ADULT; CARCINOMA; CHILD; FEMALE; FOLLOW-UP STUDIES; GERM-LINE MUTATION; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-RET; RISK FACTORS; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 33745168935     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2006.03783.x     Document Type: Article

References (55)

1. Donis-Keller H. The RET proto-oncogene and cancer. J. Intern. Med. 1995 238 : 319 25.
2. Learoyd DL Marsh DJ Richardson AL Twigg SM Delbridge L Robinson BG. Genetic testing for familial cancer. Consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia, type 2. Arch. Surg. 1997 132 : 1022 5.
3. Lips CJ Landsvater RM Hoppener JW et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N. Engl. J. Med. 1994 331 : 828 35.
4. Robinson BG. Genetic testing for multiple endocrine neoplasia. Aust. N. Z. J. Med. 1996 26 : 5 6.
5. Santoro M Carlomagno F Romano A et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995 267 : 381 3.
6. Machens A Gimm O Hinze R Hoppner W Boehm BO Dralle H. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J. Clin. Endocrinol. Metab. 2001 86 : 1104 9.
7. Machens A Niccoli-Sire P Hoegel J et al. Early malignant progression of hereditary medullary thyroid cancer. N. Engl. J. Med. 2003 349 : 1517 25.
8. Lips CJ. Clinical management of the multiple endocrine neoplasia syndromes: results of a computerized opinion poll at the Sixth International Workshop on Multiple Endocrine Neoplasia and von Hippel-Lindau disease. J. Intern. Med. 1998 243 : 589 94.
9. Machens A Brauckhoff M Holzhausen HJ Thanh PN Lehnert H Dralle H. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J. Clin. Endocrinol. Metab. 2005 90 : 3999 4003.
10. Bliss RD Gauger PG Delbridge LW. Surgeon's approach to the thyroid gland: surgical anatomy and the importance of technique. World J. Surg. 2000 24 : 891 7.
11. Evans JP Bambach CP Andrew S et al. MEN type 2a presenting as an intra-abdominal emergency. Aust. N. Z. J. Surg. 1997 67 : 824 6.
12. Norton JA Doppman JL Brennan MF. Localization and resection of clinically inapparent medullary carcinoma of the thyroid. Surgery 1980 87 : 616 22.
13. Mulligan LM Kwok JB Healey CS et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993 363 : 458 60.
14. Donis-Keller H Dou S Chi D et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet. 1993 2 : 851 6.
15. Dralle H Gimm O Simon D et al. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J. Surg. 1998 22 : 744 50 discussion 750-51.
16. Rodriguez GJ Balsalobre MD Pomares F et al. Prophylactic thyroidectomy in MEN 2A syndrome: experience in a single center. J. Am. Coll. Surg. 2002 195 : 159 66.
17. Kouvaraki MA Shapiro SE Perrier ND et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 2005 15 : 531 44.
18. Shapiro SE Cote GC Lee JE Gagel RF Evans DB. The role of genetics in the surgical management of familial endocrinopathy syndromes. J. Am. Coll. Surg. 2003 197 : 818 31.
19. Eng C Clayton D Schuffenecker I et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996 276 : 1575 9.
20. Wohllk N Cote GJ Evans DB Goepfert H Ordonez NG Gagel RF. Application of genetic screening information to the management of medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Endocrinol. Metab. Clin. North Am. 1996 25 : 1 25.
21. Yip L Cote GJ Shapiro SE et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch. Surg. 2003 138 : 409 16 discussion 416.
22. Niccoli-Sire P Murat A Rohmer V et al. Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients. J. Clin. Endocrinol. Metab. 2001 86 : 3746 53.
23. Pasini A Geneste O Legrand P et al. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain. Oncogene 1997 15 : 393 402.
24. Rossel M Pasini A Chappuis S et al. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations. Oncogene 1997 14 : 265 75.
25. Feldman GL Edmonds MW Ainsworth PJ et al. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG->ATG) mutation. Surgery 2000 128 : 93 8.
26. Frohnauer MK Decker RA. Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated? Surgery 2000 128 : 1052 7 discussion 1057-8.
27. Nilsson O Tisell LE Jansson S Ahlman H Gimm O Eng C. Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation. JAMA 1999 281 : 1587 8.
28. Lombardo F Baudin E Chiefari E et al. Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804. J. Clin. Endocrinol. Metab. 2002 87 : 1674 80.
29. Brandi ML Gagel RF Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 2001 86 : 5658 71.
30. Lips CJ Landsvater RM Hoppener JW et al. From medical history and biochemical tests to presymptomatic treatment in a large MEN 2A family. J. Intern. Med. 1995 238 : 347 56.
31. Szinnai G Meier C Komminoth P Zumsteg UW. Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. Pediatrics 2003 111 : E132 9.
32. Wells SA Jr. Baylin SB Leight GS Dale JK Dilley WG Farndon JR. The importance of early diagnosis in patients with hereditary medullary thyroid carcinoma. Ann. Surg. 1982 195 : 595 9.
33. Wells SA Jr. Chi DD Toshima K et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann. Surg. 1994 220 : 237 47 discussion 247-50.
34. Kebebew E Tresler PA Siperstein AE Duh QY Clark OH. Normal thyroid pathology in patients undergoing thyroidectomy for finding a RETgene germline mutation: a report of three cases and review of the literature. Thyroid 1999 9 : 127 31.
35. Dralle H Scheumann GF Proye C et al. The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study. J. Intern. Med. 1995 238 : 357 61.
36. Kallinowski F Buhr HJ Meybier H Eberhardt M Herfarth C. Medullary carcinoma of the thyroid-therapeutic strategy derived from fifteen years of experience. Surgery 1993 114 : 491 6.
37. Ellenhorn JD Shah JP Brennan MF. Impact of therapeutic regional lymph node dissection for medullary carcinoma of the thyroid gland. Surgery 1993 114 : 1078 81 discussion 1081-2.
38. Tamagnini P Iacobone M Sebag F Marcy M De Micco C Henry JF. Lymph node involvement in macroscopic medullary thyroid carcinoma. Br. J. Surg. 2005 92 : 449 53.
39. Noguchi S Murakami N. The value of lymph-node dissection in patients with differentiated thyroid cancer. Surg. Clin. North Am. 1987 67 : 251 61.
40. Noguchi S Noguchi A Murakami N. Papillary carcinoma of the thyroid. II. Value of prophylactic lymph node excision. Cancer 1970 26 : 1061 4.
41. Noguchi S Noguchi A Murakami N. Papillary carcinoma of the thyroid. I. Developing pattern of metastasis. Cancer 1970 26 : 1053 60.
42. Moley JF DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann. Surg. 1999 229 : 880 87 discussion 887-8.
43. Howe JR Norton JA Wells SA Jr. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery 1993 114 : 1070 77.
44. Vasen HF Nieuwenhuijzen Kruseman AC Berkel H et al. Multiple endocrine neoplasia syndrome type 2: the value of screening and central registration. A study of 15 kindreds in The Netherlands. Am. J. Med. 1987 83 : 847 52.
45. Raue F Kraimps JL Dralle H et al. Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J. Intern. Med. 1995 238 : 369 73.
46. Carling T Udelsman R. Parathyroid surgery in familial hyperparathyroid disorders. J. Intern. Med. 2005 257 : 27 37.
47. Kraimps JL Denizot A Carnaille B et al. Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. Groupe d'Etude des Tumeurs a Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons. World J. Surg. 1996 20 : 808 12 discussion 812-13.
48. Casanova S Rosenberg-Bourgin M Farkas D et al. Phaeochromocytoma in multiple endocrine neoplasia type 2 A: survey of 100 cases. Clin. Endocrinol. (Oxf.) 1993 38 : 531 7.
49. Webb TA Sheps SG Carney JA. Differences between sporadic pheochromocytoma and pheochromocytoma in multiple endocrine neoplasia, type 2. Am. J. Surg. Pathol. 1980 4 : 121 6.
50. Modigliani E Vasen HM Raue K et al. Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group. J. Intern. Med. 1995 238 : 363 7.
51. Neumann HP Berger DP Sigmund G et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N. Engl. J. Med. 1993 329 : 1531 8.
52. Brauckhoff M Gimm O Thanh PN et al. Critical size of residual adrenal tissue and recovery from impaired early postoperative adrenocortical function after subtotal bilateral adrenalectomy. Surgery 2003 134 : 1020 27 discussion 1027-8.
53. Brauckhoff M Nguyen Thanh P Bar A Dralle H Subtotal bilateral adrenalectomy preserving adrenocortical function Chirurg 2003 74 : 646 51.
54. Yip L Lee JE Shapiro SE et al. Surgical management of hereditary pheochromocytoma. J. Am. Coll. Surg. 2004 198 : 525 34 discussion 534-5.
55. Inabnet WB Caragliano P Pertsemlidis D. Pheochromocytoma: inherited associations, bilaterality, and cortex preservation. Surgery 2000 128 : 1007 11 discussion 1011-12.